RecruitingPhase 2NCT06699121

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)

Sponsor

LISCure Biosciences

Enrollment

87 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Primary Sclerosing Cholangitis (PSC)

Summary

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LB-P8 high-dose, a drug called LB-P8 low-dose, and others for people with primary sclerosing cholangitis (psc). The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLB-P8 low-dose

One capsule QD (1×10\^10 CFU/day) oral administration

DRUGLB-P8 high-dose

One capsule QD (1×10\^11 CFU/day) oral administration

DRUGPlacebo

One capsule QD oral administration

Locations(7)

University of California Davis

Sacramento, California, United States

UCHealth University of Colorado Hospital

Aurora, Colorado, United States

University Of Iowa Hospitals And Clinics

Iowa City, Iowa, United States

Mercy Medical Center

Baltimore, Maryland, United States

Mayo Clinic

Rochester, Minnesota, United States

The Vanderbilt Clinic

Nashville, Tennessee, United States

Liver institute Northwest

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06699121

Related Trials